Builder optimism fades with potential trade war looming

NEW YORK — The threat of a trade war with Canada has taken a toll on the confidence of U.S. homebuilders, according to index released Monday.

The National Association of Home Builders/Wells Fargo builder sentiment index released Monday fell two points to 68 in June. A reading of 70 in May temporarily snapped a four-month slide.

Any reading above 50 indicates more builders see sales conditions as good rather than poor. The index has remained above 60 since September 2016.

Builders' view of current sales conditions fell one point, to 75 this month. The outlook for sales over the next six months fell one point to 76. A measure of buyer traffic fell one point to 50.

"Builders are optimistic about housing market conditions as consumer demand continues to grow," said NAHB Chairman Randy Noel, "However, builders are increasingly concerned that tariffs placed on Canadian lumber and other imported products are hurting housing affordability."

The organization said higher lumber prices have added nearly $9,000 to the price of a new single-family home since January 2017.

The overall housing market remains tight, with prices of existing homes rising as demand remains strong and listings decrease. Mortgage rates are also steadily increasing, making purchases even more difficult for first-time homebuyers.

Sales of new U.S. homes fell 1.5 percent in April, according to The Commerce Department. The National Association of Realtors reported a 2.5 percent drop in existing home sales in April.

Must Read

Japan's economy slows to snail's pace as exports falter

Aug 15, 2016

Japan's economy slows in the April-June quarter, as weaker exports and business investment weigh on the faltering recovery of the world's third-largest economy

UK manufacturers see costs jump in wake of Brexit vote

Aug 16, 2016

Official figures show consumer prices in Britain rose more than expected in July, while the cost of raw materials for manufacturers are mounting as a result of the pound's drop in the wake of the vote to leave the European Union

Patent for J&J's Remicade invalidated, cheaper version looms

Aug 17, 2016

A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com